Medifast (MED) Equity Ratio (2010 - 2026)

Medifast has reported Equity Ratio for 17 years, with the latest figure at 0.78 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 4.1% year-over-year to 0.78; the trailing twelve-month figure through Mar 2026 stood at 0.78 (up 4.1% YoY), and the FY2025 full-year result was 0.8, up 8.51% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.78, down from 0.8 in the prior quarter.
• The five-year high for Equity Ratio was 0.8 in Q4 2025, with the low at 0.38 in Q2 2022.
• Historically, Equity Ratio has averaged 0.65 across 5 years, with a median of 0.7 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio slipped 28.87% — and 2023, when it surged 53.13%.
• Medifast's Equity Ratio stood at 0.49 in 2022, then soared by 32.59% to 0.65 in 2023, then advanced by 13.71% to 0.74 in 2024, then grew by 8.51% to 0.8 in 2025, then dropped by 2.23% to 0.78 in 2026.
• The last three Equity Ratio figures came in at 0.78 (Q1 2026), 0.8 (Q4 2025), and 0.8 (Q3 2025), per Business Quant data.